Young-onset colorectal cancer: treatment-related nausea, vomiting and diarrhoea

Gianluca Mauri,1,2 Martino Pedrani,1,2 Silvia Ghezzi,2 Katia Bencardino,2 Sara Mariano,2 Erica Bonazzina,2 Francesco Serra,3 Paolo Pedrazzoli,3 Riccardo Caccialanza4,4 Giulia Martina Cavestro,5 Salvatore Siena,1,2 Salvatore Artale,6 Andrea Sartore-Bianchi1,2

ABSTRACT

Objectives Early-onset colorectal cancer (EO-CRC) incidence is increasing, raising a clinical challenge. Clinicians tend to treat EO-CRC patients with more intensive regimens despite the lack of survival benefits, based on an age-related bias. Limited evidence is available regarding treatment-related toxicities in this peculiar subset of patients.

Methods We performed a literature search in MEDLINE/PubMed, EMBASE and Scopus, looking for reporting of nausea, vomiting and diarrhoea occurring in patients with EO-CRC, defined by age lower than 50 years old at initial diagnosis, while receiving anticancer treatment.

Results 2318 records were screened and 9 full-text articles were considered eligible for inclusion for a total of 59783 patients (of whom 8681 EO-CRC patients). We found nausea and vomiting occurring at higher incidence among EO-CRC compared with older patients, while no difference was reported as for diarrhoea. Peritoneal involvement, age younger than 40, female gender, suboptimal adherence to clinical guidelines and oxaliplatin might represent potential risk factors for increased nausea and vomiting in patients with EO-CRC.

Conclusion EO-CRC patients experience more nausea and vomiting but equal or less diarrhoea compared with older patients. Adherence to clinical guidelines is recommended, and more data are warranted to assess if an enhanced antiemetic prophylactic might be an option to improve treatment tolerability in young patients with CRC.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Patients with early-onset colorectal cancer (EO-CRC) often receive more intensive cytotoxic regimens without achieving survival benefits, while few data are available on toxicities experienced by this peculiar patients’ population.

WHAT THIS STUDY ADDS

⇒ Unexpectedly, patients with EO-CRC suffer more nausea and vomiting compared with older patients. Oxaliplatin, peritoneal involvement, age younger than 40, female gender and a low body mass index might play a role as potential risk factors of increased nausea and vomiting.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Based on this initial data, dedicated studies are warranted to define if enhancing primary antiemetic prophylactic might be an option to improve treatment tolerability in young patients with CRC.

INTRODUCTION

In the USA, colorectal cancer (CRC) recently became the first and second cause of cancer death among adult male and female between 20 and 50 years of age, respectively. This is the epidemiological consequence of a steady CRC incidence increase by 1%–4% per year, which has been reported worldwide since the early 90s.1

Early-onset CRC (EO-CRC) commonly defines CRCs diagnosed in adults earlier than 50 years of age, based on the empirically predefined age screening cut-off.1 Most of EO-CRC are sporadic and usually occur in the left side of the colon or rectum, with peculiar clinicopathological features.1 EO-CRC patients prognosis is harshly debated and no clear-cut data emerged due to wide heterogeneity of data available mainly in terms of stages and treatments provided.1 Despite these partial data, based on an age-related bias, clinicians are prone to treat EO-CRC patients with more aggressive medical...
regimens. Furthermore, very little is known on the toxicity burden experienced under treatment by this subset of patients.

Here, we review the available literature to address the burden of nausea, vomiting and diarrhoea experienced by patients with EO-CRC receiving standard CRC treatments. We focused on these toxicities given their prevalence and impact on patients’ quality of life.

MATERIALS AND METHODS
The purpose of this systematic review is to evaluate the burden of nausea, vomiting and diarrhoea occurring in patients with EO-CRC undergoing systemic medical treatments.

We reviewed MEDLINE/PubMed, EMBASE and Scopus for citation from December 1962 to March 19th, 2023. The Medical Subject Headings terms used for the search in PubMed were (young[Title/Abstract] OR early onset)[Title/Abstract] AND (gastrointestinal[Title/Abstract] OR nausea[Title/Abstract] OR vomiting[Title/Abstract] OR diarrhea[Title/Abstract] OR diarrhoea[Title/Abstract] AND (colorectal adenocarcinoma[Title/Abstract] OR colorectal[Title/Abstract] OR CRC[Title/Abstract] OR colon[Title/Abstract] OR rectal)[Title/Abstract]. The Medical Subject Headings used for the search both in EMBASE were (young:ab,ti OR ‘early onset’:ab,ti) AND (gastrointestinal:ab,ti OR ‘nausea’:ab,ti OR ‘vomiting’:ab,ti OR ‘diarrhea’:ab,ti OR ‘diarrhoea’:ab,ti) AND (colorectal adenocarcinoma:ab,ti OR colorectal:ab,ti OR crc:ab,ti OR colon:ab,ti OR rectal:ab,ti). The Medical Subject Headings used for the search in Scopus were TITTLE-ABS-KEY ((young OR early AND onset) AND (gastrointestinal OR nausea OR vomiting OR diarrhoea OR diarrhoea) AND (colorectal AND adenocarcinoma OR colorectal OR crc OR colon OR rectal).

Inclusion criteria were the following: full-text articles of studies reporting on or reviewing nausea, vomiting and/or diarrhoea occurring in patients with CRC diagnosed earlier than 50 years of age and treated with systemic medical regimens. The exclusion criteria were: publications written in language other than English, the inclusion of patients older than 50 years of age and/or younger than 18 among EO-CRC population. Full-text selection and data extraction was carried out by two reviewers with inter-rater agreement (MP and GM). Data concerning clinical study type, prevalence and severity of nausea, vomiting and diarrhoea, and treatment regimens administered were reviewed to look for differences between patients with EO-CRC and their older counterpart. Finally, collected data, table and manuscript were then reviewed by other authors ahead of submission.

RESULTS
Out of 2318 screened, 38 records were identified through database searching (PUBMED, EMBASE and SCOPUS) plus 3 additional records by manual searching through bibliographies of selected manuscript (online supplemental figure 1). Nine records were eligible for inclusion, all being full-text articles3-11 accounting for a total of 59783 patients of whom 8681 patients with EO-CRC) (table 1). Most of the studies included CRC only patients. However, some of the studies were included despite considering also other tumour types provided that the burden of nausea, vomiting and diarrhoea were described separately from non-CRC histology.6-8

Nausea and vomiting in EO-CRC
The incidence of nausea in patients with EO-CRC was reported significantly higher as compared with the older counterpart in all the studies dealing this topic.3-7 9-11

In the adjuvant setting, a post hoc analysis on 16349 patients from the IDEA trial described a higher incidence of nausea and vomiting in EO-CRC.3 Importantly, one study did not report any difference in nausea, vomiting or diarrhoea incidence considering 50 years of age as upper limit cut-off, while confirmed the same trend presented in other studies with a higher incidence of nausea and vomiting in the subset of EO-CRC younger than age 40 (10% vs 7%, OR 0.64, p 0.04).5

In the metastatic setting, Blanke et al4 reported a higher prevalence of grade 3 or higher nausea in EO-CRC. In addition, in TRIBE and TRIBE2 trials EO-CRC had a higher risk of nausea and vomiting.9 The authors suggested that these results might be related to a higher percentage of females among the youngers.9 A similar but not-statistically significant higher rate of any grade nausea (43% vs 32%, p=0.249) and vomiting (26% vs 16%, p=0.226) has been described in EO-CRC patients with advanced RAS wild-type mCRC treated with FOLFLEX plus panitumumab within the Valantina clinical trial.10 Similarly, Meng et al, dividing in three age subgroups patients treated with first line FOLFLEX (<50 years vs 50–65 years vs >65 years), identified differences in incidence of nausea/vomiting (69.3% vs 57.6% vs 60.4%, p=0.019), and the EO-CRC group had also earlier onset of nausea/vomiting (1.0 vs 2.1 vs 2.6 weeks, p=0.012).11

In a population of both non-metastatic and metastatic CRC patients, similar findings were obtained with patients with EO-CRC being more likely to report nausea and vomiting.6 Finally, in one study female gender and age lower than 50 were significantly associated with the onset of gastrointestinal toxicities.7

Diarrhoea in EO-CRC
Differently from data concerning nausea and vomiting, patients with EO-CRC were found to suffer same or less diarrhoea compared with their older counterpart both in the adjuvant and the metastatic setting.3 8-11
<table>
<thead>
<tr>
<th>Authors, ref</th>
<th>Country</th>
<th>Study setting/study type</th>
<th>Total n of participants (cases; controls)</th>
<th>EO-CRC age cut-off (years of age)</th>
<th>Gender F/M (%)</th>
<th>Control cohort</th>
<th>Treatment provided</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raimondi et al, 2022</td>
<td>Italy</td>
<td>Adv./post hoc analysis of Valentino trial</td>
<td>229 (35;194)</td>
<td>&lt;50</td>
<td>34/66</td>
<td>Yes</td>
<td>FOLFOX plus panitumumab first-line treatment</td>
<td>▶ EO-CRC experienced higher rate of any grade nausea (43% vs 32%, p=0.249) and vomiting (26% vs 16%, p=0.220).</td>
</tr>
<tr>
<td>Meng et al, 2022</td>
<td>USA</td>
<td>Adv./post hoc analysis of 3 clinical trials (NCT00272051; NCT 00305188; NCT00364013)</td>
<td>1223 (179;1044)</td>
<td>&lt;50, 50–65, &gt;65</td>
<td>40/60</td>
<td>Yes</td>
<td>FOLFOX</td>
<td>▶ EO-CRC (&lt;50 yo vs 50–65 years vs &gt;65 years) had higher incidence of nausea and vomiting (69.3% vs 57.6% vs 60.4%, p=0.019). ▶ Lower incidence of severe diarrhoea in EO-CRC pts (6.1% vs 9.1% vs 13.0%, p=0.02).</td>
</tr>
<tr>
<td>Antoniotti et al, 2022</td>
<td>Italy</td>
<td>Adv./post hoc analysis of TRIBE and TRIBE2 studies</td>
<td>1187 (194; 993)</td>
<td>&lt; 50</td>
<td>42/58</td>
<td>Yes</td>
<td>FOLFOXIRI+bevacizumab or doublets+bevacizumab</td>
<td>▶ EO-CRC had lower risk of diarrhoea (9% vs 14%, p=0.04) and higher of nausea and vomiting (69% vs 57%, p&lt;0.01; 44% vs 32%, p&lt;0.01). ▶ Among pts receiving FOLFOXIRI/bevacizumab, the incidence of G3-G4 GI adverse events (mucositis, nausea, diarrhoea) was not signficantly different in EO-CRC.</td>
</tr>
<tr>
<td>Fontana et al, 2021</td>
<td>International</td>
<td>Adv./post hoc analysis of the IDEA cohort</td>
<td>16 349 (1564; 14785)</td>
<td>&lt; 50</td>
<td>43.6/56.4</td>
<td>Yes</td>
<td>CAPOX or FOLFOX (3 or 6 months)</td>
<td>▶ Higher incidence of nausea/vomiting (58.2% vs 44.8% p&lt;0.0001; 22.3% vs 16.1% p&lt;0.0001) but not diarrhoea (42.1% vs 39.4% p=0.3765) in pts with EO-CRC.</td>
</tr>
<tr>
<td>Perl et al, 2016</td>
<td>Israel</td>
<td>Adj. and Adv./retrospective cohort</td>
<td>50 pts with GI malignancies (80% were CRC pts) (40; 0)</td>
<td>&lt; 40</td>
<td>52/48</td>
<td>No</td>
<td>Surgery, chemotherapy, radiotherapy, combined modality</td>
<td>▶ Diarrhoea and abdominal pain significantly increased during treatment administration (p&lt;0.05) in EO-CRC pts.</td>
</tr>
<tr>
<td>Suzuki et al, 2016</td>
<td>Japan</td>
<td>N.S./retrospective</td>
<td>179 (22; 157)</td>
<td>&lt; 50</td>
<td>39/61</td>
<td>Yes</td>
<td>FOLFOX, XELOX, FOLFIRI</td>
<td>▶ Female (OR 2.870, 95% CI 1.139 to 7.228; p=0.025)* and age &lt;50 (OR 4.277; 95% CI 1.472 to 12.424; p=0.008) were risk factors for CINV.</td>
</tr>
<tr>
<td>Sanford et al, 2014</td>
<td>USA</td>
<td>Adj. and Adv./multicentric prospective study</td>
<td>1544 breast cancer and 718 CRC (37; 681)</td>
<td>&lt; 40</td>
<td>48/52</td>
<td>Yes</td>
<td>N.S.</td>
<td>▶ EO-CRC pts had more nausea (adjusted OR 2.59, 95% CI 1.02 to 6.59 p&lt;0.05), while GI-G4 diarrhoea, vomiting or mucositis were not significantly different.</td>
</tr>
<tr>
<td>Hubbard et al, 2012</td>
<td>International</td>
<td>Adv./post hoc analysis of 10 randomised phase III trials</td>
<td>33 574 (5,817; 27 757)</td>
<td>&lt; 40 and &lt; 50†</td>
<td>45/55</td>
<td>Yes</td>
<td>Fluorouracil-based monotherapy and combination chemotherapy</td>
<td>▶ EO-CRC &lt;40: more nausea and vomiting (10% vs 7%, OR 0.64 p=0.04), but no difference in diarrhoea (15% vs 16%, p=0.05).</td>
</tr>
<tr>
<td>Blanke et al, 2011</td>
<td>International</td>
<td>Adv./post hoc analysis of 9 phase III trials</td>
<td>62 84 (793; 5491)</td>
<td>&lt; 50</td>
<td>36.5/63.5</td>
<td>Yes</td>
<td>Fluorouracil-based monotherapy and combination chemotherapy</td>
<td>▶ More G3 nausea (10% vs 7%, p=0.01); rarer severe diarrhoea (11% vs 14% p=0.001) in patients with EO-CRC.</td>
</tr>
</tbody>
</table>

*Reported as a potential factor influencing a higher gastrointestinal symptoms incidence in EO-CRC cohort. 
†Number of patients included in the younger than 50 years of age cohort. 
‡Two cohorts of patients with EO-CRC were studied. Nausea grading is reported according to Common Terminology Criteria for Adverse Events (CTCAE). 
Adj, Adjuvant setting; Adv, Advanced/metastatic setting; CINV, chemotherapy-induced nausea or vomiting; F, female; G, grade; GI, gastrointestinal; LO-CRC, later-onset colorectal cancer; M, male; n, number; Neoadj, neoadjuvant; N.S., not specified; Prosp, prospective; Pts, patients; ref, reference; Retro, retrospective.
In one study conducted in the adjuvant setting, any grade diarrhoea during treatment was observed in 37% of patients with EO-CRC younger than 40 years (control cohort not available).8 In the same setting,4 while in the IDEA trial cohort no increased in diarrhoea incidence was noticed among patients with EO-CRC.3

Moreover, even in the advanced setting when receiving a triplet combination, patients with EO-CRC had a lower risk of diarrhoea.9 Similarly, Meng and et al11 found lower incidence of severe diarrhoea (6.1% vs 9.1% vs 13.0%, p=0.02) in patients with EO-CRC treated with first line FOLFOX. Also from the Valen- tino trial, no significant differences in any grade diarrhoea (54% vs 52%, p=0.853) were reported.10

DISCUSSION

In our review, we found that patients with EO-CRC suffer more nausea and vomiting compared to older patients receiving systemic anticancer treatments. Data available in retrieved articles did not allow us to precisely define the impact of each specific anticancer regimen on nausea and vomiting. However, given its prevalence of administration and its emetogenicity, oxaliplatin might be regarded as a potential risk factor of increased nausea and vomiting in patients with EO-CRC.12

Nausea and vomiting represent a multifactorial symptom and the primary cause is often difficult to assess. Accordingly, all but one articles retrieved do not differentiate its cause.2 Indeed, there are several potential causes leading to an increased burden of nausea and vomiting in patients with EO-CRC, which might also be differently prevalent from older patients. First, EO-CRC patients more frequently receive more intense cytotoxic combinations, including multiple drugs with moderate emetogenic potential, and this might explain more nausea and vomiting.2 12 Second, it should be noted that the reported higher prevalence of peritoneal involvement in EO-CRC, particularly in patients with mucinous or signet-ring CRC, might impact on the burden of nausea and vomiting.12 Third, the burden of nausea and vomiting in EO-CRC has been reported to increase among those younger than 40 years of age,5 6 which has been postulated to be potentially related to psychological consequences and emotional stress of a cancer diagnosis at a very young age. Moreover, it has been reported that younger female patients, particularly if with low body mass index according to data from a CRC population ranging between 40 and 65 years of age, might suffer more nausea and vomiting.7 Finally, based on data from other young patients with cancer cohorts not limited to EO-CRC, physicians suboptimal adherence to international guidelines for the management of nausea and vomiting treating younger patients might represent an additional risk factor.8 Indeed, based on an age-related bias, patients with EO-CRC might be expected to better tolerate medical systemic treatments and consequently be undertreated for side effects. However, according to data available so far in the literature, this attitude should be discouraged. Indeed, we suggest patients with EO-CRC to be treated for nausea and vomiting as stated in European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) guidelines for the overall cancer population.12

Differently from nausea and vomiting, we found that the burden of diarrhoea experienced by patients with EO-CRC is overall comparable or lower to the older counterpart.3 Thus, diarrhoea does not emerge as a specific issue among the gastrointestinal toxicity burden experienced by patients with EO-CRC.

Our review has some limitations such as the few data available on this topic and the heterogeneity of records retrieved hampering the drawing of definitive conclusion. Most of the studies retrieved are secondary analysis of randomised clinical trials whose first aim was not to address EO-CRC specific outcomes, leading to the lack of a proper matched control population. Moreover, the lack of grading for nausea, vomiting and diarrhoea in most of the studies retrieved hampered the understanding of the actual impact of these toxicities on EO-CRC patients quality of life (QoL). Accordingly, towards any clinical implementation more data are mandatory.

In conclusion, given the limited amount of data on this topic in this specific subset of patients, nausea and vomiting in patients with EO-CRC should be managed as recommended in the ASCO and ESMO clinical guidelines for the general CRC population. Further dedicated and prospective studies are warranted to define if enhancing primary antiemetic prophylactic might be an option to improve treatment tolerability and QoL in patients with EO-CRC.

Author affiliations

1Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano, Italy
2Department of Hematology, Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milano, Italy
3Medical Oncology Unit and Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy
4Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
5Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milano, Italy
6Department of Medical Oncology, Vimmerbate Hospital, ASST Brianza, Vimmerbate, Italy

Acknowledgements AS-B, SS, GM, MP, SG, SM, KB and EB are supported by Fondazione Oncologia Niguarda Onlus.

Contributors AS-B, SA and GM conceived the short report. GM, MP, SG and SM collected data and GM, MP, AS-B and SS wrote the manuscript. KB, GMC, PP, RC, FS and EB critically reviewed the manuscript.

Funding Fondazione Regionale per la Ricerca Biomedica Regione Lombardia (Project CP 12/2018 IANG CRC) to SS and AS-B.
Competing interests SS is advisory board member for Amgen, Bayer, BMS, CheckmAb, Daiichi-Sankyo, Guardant Health, Merck, Novartis, Roche-Genentech and Seagen. AS-B is advisory board member for Amgen, Bayer, Sanofi and Servier. GM received honoraria from COR2ED. The other authors declare no conflicts of interest.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iDs
Riccardo Caccialanza http://orcid.org/0000-0002-9379-3569
Andrea Sartore-Bianchi http://orcid.org/0000-0003-0780-0409

REFERENCES